News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
734,396 Results
Type
Article (50840)
Company Profile (302)
Press Release (683254)
Section
Business (216097)
Career Advice (2539)
Deals (36574)
Drug Delivery (100)
Drug Development (84753)
Employer Resources (176)
FDA (16888)
Job Trends (15689)
News (364440)
Policy (34960)
Tag
Academia (2820)
Alliances (52962)
Alzheimer's disease (1287)
Approvals (16799)
Artificial intelligence (141)
Bankruptcy (359)
Best Places to Work (11985)
Biotechnology (207)
Breast cancer (120)
Cancer (1066)
Cardiovascular disease (91)
Career advice (2127)
Cell therapy (230)
Clinical research (66943)
Collaboration (376)
Compensation (188)
COVID-19 (2670)
C-suite (91)
Data (1024)
Diabetes (158)
Diagnostics (6372)
Drug pricing (91)
Earnings (88528)
Employer resources (154)
Events (116938)
Executive appointments (283)
FDA (17391)
Funding (330)
Gene therapy (179)
GLP-1 (638)
Government (4709)
Healthcare (19767)
Infectious disease (2756)
Inflammatory bowel disease (110)
Interviews (440)
IPO (16587)
Job creations (4059)
Job search strategy (1799)
Layoffs (446)
Legal (8640)
Lung cancer (170)
Manufacturing (173)
Medical device (13698)
Medtech (13703)
Mergers & acquisitions (20031)
Metabolic disorders (426)
Neuroscience (1561)
NextGen Class of 2024 (7014)
Non-profit (4845)
Northern California (1392)
Obesity (248)
Opinion (214)
Patents (101)
People (59499)
Phase I (20701)
Phase II (29331)
Phase III (22063)
Pipeline (375)
Postmarket research (2886)
Preclinical (9029)
Radiopharmaceuticals (243)
Rare diseases (211)
Real estate (6324)
Regulatory (22924)
Research institute (2504)
Resumes & cover letters (415)
Southern California (1243)
Startups (3786)
United States (13081)
Vaccines (600)
Weight loss (194)
Date
Today (299)
Last 7 days (1029)
Last 30 days (3685)
Last 365 days (36711)
2024 (32808)
2023 (41295)
2022 (52551)
2021 (57263)
2020 (55990)
2019 (49118)
2018 (37176)
2017 (34073)
2016 (34132)
2015 (40119)
2014 (34329)
2013 (29829)
2012 (31762)
2011 (32184)
2010 (30740)
Location
Africa (893)
Arizona (197)
Asia (40954)
Australia (6840)
California (3143)
Canada (1237)
China (243)
Colorado (137)
Connecticut (151)
Europe (90973)
Florida (432)
Georgia (113)
Illinois (359)
Indiana (199)
Kansas (97)
Maryland (574)
Massachusetts (2532)
Michigan (154)
Minnesota (266)
New Jersey (924)
New York (921)
North Carolina (736)
Northern California (1392)
Ohio (137)
Pennsylvania (811)
South America (1286)
Southern California (1243)
Texas (430)
Washington State (350)
734,396 Results for "w l gore and associates inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
FDA
W. L. Gore & Associates, Inc. Receives U.S. Food & Drug Administration (FDA) Approval for Lower Profile Gore® Viabahn® VBX Balloon Expandable Endoprosthesis, Now 6 FR Sheath Compatible
As part of efforts to continuously improve medical solutions for patients with complex vascular disease, W. L. Gore & Associates, Inc. announced recent FDA approval of a lower profile GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis.
January 31, 2024
·
4 min read
GORE ANNOUNCES FIRST PATIENT IMPLANT IN THE ARISE II PIVOTAL STUDY OF THE GORE® ASCENDING STENT GRAFT
W. L. Gore & Associates (Gore) announced the first patient implantation of the GORE® Ascending Stent Graft in the ARISE II Trial, an exciting step in the development of treatments for pathologies involving the ascending aorta using endovascular repair rather than traditional open surgery.
December 20, 2023
·
3 min read
BioCapital
Gore PharmBIO Introduces 250mL, 500mL and 1L Protein Capture Devices With Protein A to Deliver Consistent Scalability and Increased Productivity Across Sizes
W. L. Gore & Associates, Inc. (“Gore”), a global materials science company, continues to build on its growing portfolio of protein capture devices with the introduction of its 250mL, 500mL and 1L GORE® Protein Capture Devices with Protein A.
April 4, 2023
·
2 min read
BioMidwest
Gore Initiates Study to Compare the Gore® Viabahn® VBX Balloon Expandable Endoprosthesis to Bare Metal Stents
W. L. Gore & Associates announced the initiation of the Gore VBX FORWARD Clinical Study to compare the VBX Stent Graft to bare metal stenting for patients with complex iliac occlusive disease.
June 13, 2023
·
5 min read
Gore announces first U.S. enrollment for the GORE® VIAFORT Vascular Stent iliofemoral Study
W. L. Gore & Associates (Gore) has announced that the first U.S. patient has been enrolled in a prospective, non-randomized, multicenter, single-arm study with five-year follow-up (NCT05489588) to evaluate the investigational GORE® VIAFORT Vascular Stent for the treatment of symptomatic iliofemoral venous obstruction.
June 6, 2023
·
2 min read
Business
Arzeda Announces Collaboration with W. L. Gore & Associates to Drive Innovation in Materials Research with Designer Proteins
Arzeda, the industry-leading Protein Design Company™, announced today that it is collaborating with W. L. Gore & Associates, a global leader in advanced materials science, on research leveraging Arzeda’s technology platform that economically and efficiently creates new and enhances existing proteins.
June 27, 2022
·
2 min read
GORE ANNOUNCES FIRST U.S. ENROLLMENT FOR THE GORE® VIAFORT VASCULAR STENT IVC STUDY
W. L. Gore & Associates (Gore) has announced that the first U.S. patient has been enrolled in a prospective, non-randomized, multicenter, single-arm study with 5-year follow-up (NCT05409976) to evaluate the investigational GORE® VIAFORT Vascular Stent for the Treatment of Symptomatic Inferior Vena Cava (IVC) Obstruction with or without combined Iliofemoral Obstruction.
March 28, 2023
·
2 min read
Deals
Agile Therapeutics Inc. Announces Definitive Merger Agreement with Insud Pharma, S.L.
Agile Therapeutics, Inc. today announced that it has entered into a definitive merger agreement (“Merger Agreement”) with Insud Pharma, S.L.
June 26, 2024
·
10 min read
GORE COMPLETES FIRST IN-HUMAN IMPLANTS OF THE GORE® VIAFORT VASCULAR STENT
W. L. Gore & Associates (Gore) today announced the first implants of its investigational GORE® VIAFORT Vascular Stent as part of the recently initiated GORE VIAFORT Device Pivotal Clinical Study, (i.e., prospective, multicenter, non-randomized, single-arm study NCT05409976) for the treatment of inferior vena cava (IVC) occlusive disease with or without iliofemoral vein involvement.
October 28, 2022
·
3 min read
Business
AGC Biologics and Gore Collaborate on New Protein A-based Purification Technology and Contract Manufacturing Services for Antibody Therapies
AGC Biologics , a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a collaboration with W.L. Gore & Associates (Gore) that features Protein A affinity purification technology from Gore alongside the CDMO’s contract development and manufacturing services.
December 12, 2022
·
2 min read
1 of 73,440
Next